AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30642372 — intervention group
Group type: EXPERIMENTAL
Intervention: Chiauranib 65 mg/day
Number of subjects: 18
Study 30642372 — intervention group
Group type: EXPERIMENTAL
Intervention: Chiauranib 50 mg/day
Number of subjects: 18
Study 30642372 — intervention group
Group type: EXPERIMENTAL
Intervention: Chiauranib (various doses from 10 to 65 mg/day)
Number of subjects: 18
Study 30642372 — intervention group
Group type: EXPERIMENTAL
Intervention: Chiauranib
Number of subjects: 18
Study 30642373 — intervention group
Group type: EXPERIMENTAL
Intervention: JS001 (anti-PD-1 antibody)
Number of subjects: 36
Study 30642415 — intervention group
Group type: EXPERIMENTAL
Intervention: Amisulpride (6 weeks treatment)
Number of subjects: 22
Study 30642537 — intervention group
Group type: EXPERIMENTAL
Intervention: Afatinib (first-line treatment, modified starting dose of ≤30 mg for 31.1% of patients, 40 mg starting dose for others)
Number of subjects: 228
Study 30642537 — intervention group
Group type: EXPERIMENTAL
Intervention: Afatinib (40 mg starting dose)
Number of subjects: 228
Study 30642545 — intervention group
Group type: EXPERIMENTAL
Intervention: ASC plus vinorelbine
Number of subjects: 409
Study 30642545 — intervention group
Group type: EXPERIMENTAL
Intervention: ASC plus mitomycin, vinblastine and cisplatin (MVP)
Number of subjects: 409
Study 30642545 — intervention group
Group type: COMPARATOR
Intervention: Active symptom control (ASC)
Number of subjects: 409
Study 30642819 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib (420 mg or 560 mg daily) + Nivolumab (3 mg/kg every 2 weeks)
Number of subjects: 141
Study 30642819 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib + Nivolumab
Number of subjects: 141
Study 30643112 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressurized intraperitoneal aerosol chemotherapy (PIPAC) with oxaliplatin 92 mg/m² or cisplatin 7.5 mg/m² and doxorubicin 1.5 mg/m², repeated every 6 weeks
Number of subjects: 2
Study 30643112 — intervention group
Group type: EXPERIMENTAL
Intervention: PIPAC procedures
Number of subjects: 2
Study 30643152 — intervention group
Group type: EXPERIMENTAL
Intervention: ad hoc designed polychromatic-flowcytometry (PFC) Lyotube
Number of subjects: 50
Study 30643152 — intervention group
Group type: COMPARATOR
Intervention: CellSearch system
Number of subjects: 50
Study 30643152 — intervention group
Group type: EXPERIMENTAL
Intervention: Both counting procedures (PFC and CellSearch)
Number of subjects: 50
Study 30643455 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole plus goserelin (ADD group)
Number of subjects: 62
Study 30643455 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen (TAM group)
Number of subjects: 62
Study 30644132 — intervention group
Group type: EXPERIMENTAL
Intervention: Sample enrichment recruitment methods
Number of subjects: 0
Study 30644132 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariate risk score (MRS)
Number of subjects: 0
Study 30644132 — intervention group
Group type: EXPERIMENTAL
Intervention: Statistical modeling of identified markers
Number of subjects: 0
Study 30644585 — intervention group
Group type: EXPERIMENTAL
Intervention: Cangrelor as a bridge therapy
Number of subjects: 0
Study 30644648 — intervention group
Group type: EXPERIMENTAL
Intervention: rs295137 in SPATS2L
Number of subjects: 591
Study 30644648 — intervention group
Group type: EXPERIMENTAL
Intervention: rs7037276 in IL33
Number of subjects: 591
Study 30644648 — intervention group
Group type: EXPERIMENTAL
Intervention: rs1342326 in IL33
Number of subjects: 591
Study 30644817 — intervention group
Group type: EXPERIMENTAL
Intervention: Focused ultrasound-mediated hyperthermia for targeted drug delivery
Number of subjects: 10
Study 30645028 — intervention group
Group type: EXPERIMENTAL
Intervention: LYR-210
Number of subjects: 20
Study 30645176 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary feeding pattern during short-term bed rest
Number of subjects: 20
Study 30646370 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-centered education bundle intervention
Number of subjects: 19652
Study 30646370 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 19652
Study 30646375 — intervention group
Group type: EXPERIMENTAL
Intervention: Return to work within 12 months after acute myocardial infarction
Number of subjects: 1566
Study 30646375 — intervention group
Group type: EXPERIMENTAL
Intervention: Reasons for not returning to work
Number of subjects: 1566
Study 30646375 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors associated with returning to work
Number of subjects: 1566
Study 30646425 — intervention group
Group type: EXPERIMENTAL
Intervention: Cataract surgery at ages 27 and 36 years for patients 1 and 2 respectively
Number of subjects: 3
Study 30646872 — intervention group
Group type: EXPERIMENTAL
Intervention: Bernese Pain Scale for Neonates (BPSN)
Number of subjects: 154
Study 30646872 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart rate measurement
Number of subjects: 154
Study 30646872 — intervention group
Group type: EXPERIMENTAL
Intervention: Gestational age (GA)
Number of subjects: 154
Study 30646872 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified BPSN
Number of subjects: 154
Study 30646942 — intervention group
Group type: EXPERIMENTAL
Intervention: SNP rs1004819 located on IL23R
Number of subjects: 645
Study 30646942 — intervention group
Group type: EXPERIMENTAL
Intervention: SNP rs27434 located on ERAP1
Number of subjects: 645
Study 30646942 — intervention group
Group type: EXPERIMENTAL
Intervention: Haplotype CCT of ERAP1
Number of subjects: 645
Study 30646942 — intervention group
Group type: EXPERIMENTAL
Intervention: IL23R locus
Number of subjects: 645
Study 30646942 — intervention group
Group type: COMPARATOR
Intervention: BASDAI, ASDAS-CRP, CRP, Berlin MRI score
Number of subjects: 645
Study 30647051 — intervention group
Group type: COMPARATOR
Intervention: Moderate risk group (n=1663)
Number of subjects: 4957
Study 30647051 — intervention group
Group type: COMPARATOR
Intervention: High risk group (n=144)
Number of subjects: 4957
Study 30647082 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-PD-1 therapy
Number of subjects: 0
Study 30648126 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalbavancin (1500 mg IV on days 1 and 8)
Number of subjects: 80
Study 30648126 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SOC) for osteomyelitis (oral or IV) per investigator judgment for 4-6 weeks
Number of subjects: 80
Study 30648126 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalbavancin
Number of subjects: 80
Study 30648126 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SOC)
Number of subjects: 80
Study 30648632 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib 50 mg/day individualized schedule
Number of subjects: 117
Study 30648932 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV13 followed by PPSV23 or PCV13 1 year later
Number of subjects: 962
Study 30648932 — intervention group
Group type: COMPARATOR
Intervention: PPSV23 followed by PCV13 1 year later
Number of subjects: 962
Study 30648932 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV13 (first dose)
Number of subjects: 962
Study 30649177 — intervention group
Group type: EXPERIMENTAL
Intervention: Onclarity HPV assay
Number of subjects: 33858
Study 30649177 — intervention group
Group type: COMPARATOR
Intervention: Hybrid Capture 2
Number of subjects: 33858
Study 30649404 — intervention group
Group type: EXPERIMENTAL
Intervention: Progesterone (P4) exposure during ovulatory cycles with normal or short luteal phase lengths
Number of subjects: 23
Study 30649404 — intervention group
Group type: COMPARATOR
Intervention: Anovulatory cycles without P4 or Pd exposure
Number of subjects: 23
Study 30649445 — intervention group
Group type: EXPERIMENTAL
Intervention: Grading scale (TRANSSPHER grade) based on preoperative MRI characteristics
Number of subjects: 222
Study 30649445 — intervention group
Group type: EXPERIMENTAL
Intervention: Validation cohort using the grading scale (TRANSSPHER grade)
Number of subjects: 222
Study 30649524 — intervention group
Group type: EXPERIMENTAL
Intervention: TCZ-SC monotherapy + GC (5 mg/day)
Number of subjects: 1804
Study 30649524 — intervention group
Group type: EXPERIMENTAL
Intervention: TCZ-SC monotherapy without GC
Number of subjects: 1804
Study 30649524 — intervention group
Group type: EXPERIMENTAL
Intervention: TCZ-SC combination therapy + GC (5 mg/day)
Number of subjects: 1804
Study 30649524 — intervention group
Group type: EXPERIMENTAL
Intervention: TCZ-SC combination therapy without GC
Number of subjects: 1804
Study 30649524 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment subgroups (TCZ-SC with or without GC)
Number of subjects: 1804
Study 30650259 — intervention group
Group type: EXPERIMENTAL
Intervention: Plazomicin (15 mg/kg administered by 30-minute intravenous infusion)
Number of subjects: 56
Study 30650259 — intervention group
Group type: EXPERIMENTAL
Intervention: Plazomicin (20 mg/kg administered by 30-minute intravenous infusion)
Number of subjects: 56
Study 30650259 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 30650259 — intervention group
Group type: COMPARATOR
Intervention: Oral moxifloxacin (400 mg)
Number of subjects: 56
Study 30651126 — intervention group
Group type: EXPERIMENTAL
Intervention: Avelumab (10 mg/kg)
Number of subjects: 51
Study 30651141 — intervention group
Group type: EXPERIMENTAL
Intervention: mRSS improvement at 12 months
Number of subjects: 0
Study 30651141 — intervention group
Group type: EXPERIMENTAL
Intervention: mRSS MCID improvement criteria met
Number of subjects: 0
Study 30651193 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher DII scores (pro-inflammatory diet) in the SUN cohort
Number of subjects: 25356
Study 30651193 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher DII scores (pro-inflammatory diet) in the PREDIMED cohort
Number of subjects: 25356
Study 30651193 — intervention group
Group type: EXPERIMENTAL
Intervention: Meta-analysis of 12 cohorts including SUN and PREDIMED
Number of subjects: 25356
Study 30651576 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher energy expenditure (EE)
Number of subjects: 307
Study 30651576 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive restraint
Number of subjects: 307
Study 30651576 — intervention group
Group type: EXPERIMENTAL
Intervention: Disinhibition
Number of subjects: 307
Study 30651576 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjusted 24-h EE in Native Americans
Number of subjects: 307
Study 30651576 — intervention group
Group type: EXPERIMENTAL
Intervention: Disinhibition in Native Americans
Number of subjects: 307
Study 30651576 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher 24-h EE
Number of subjects: 307
Study 30651576 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater 24-h EE
Number of subjects: 307
Study 30651576 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher 24-h EE in non-Native Americans
Number of subjects: 307
Study 30651747 — intervention group
Group type: EXPERIMENTAL
Intervention: VD deficient (VDD)
Number of subjects: 2641
Study 30651747 — intervention group
Group type: EXPERIMENTAL
Intervention: VD insufficient (VDI)
Number of subjects: 2641
Study 30651747 — intervention group
Group type: EXPERIMENTAL
Intervention: VD sufficient (VDS)
Number of subjects: 2641
Study 30652145 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic IVC filters
Number of subjects: 104
Study 30653209 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI before surgery
Number of subjects: 339
Study 30653209 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI findings
Number of subjects: 339
Study 30653209 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient preference
Number of subjects: 339
Study 30653209 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive margins after attempted WLE
Number of subjects: 339
Study 30653209 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive genetic test results
Number of subjects: 339
Study 30653209 — intervention group
Group type: EXPERIMENTAL
Intervention: Contraindication to radiotherapy
Number of subjects: 339
Study 30653209 — intervention group
Group type: EXPERIMENTAL
Intervention: WLE after MRI
Number of subjects: 339
Study 30653209 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy guided by DCIS score
Number of subjects: 339
Study 30653209 — intervention group
Group type: EXPERIMENTAL
Intervention: DCIS score
Number of subjects: 339
Study 30653530 — intervention group
Group type: EXPERIMENTAL
Intervention: Substance use
Number of subjects: 906
Study 30653530 — intervention group
Group type: EXPERIMENTAL
Intervention: Gang activity
Number of subjects: 906
Study 30653530 — intervention group
Group type: EXPERIMENTAL
Intervention: Older age
Number of subjects: 906
Study 30653530 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher stress levels
Number of subjects: 906
Study 30653530 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower education levels
Number of subjects: 906
Study 30653530 — intervention group
Group type: EXPERIMENTAL
Intervention: Better community infrastructure
Number of subjects: 906
Study 30653530 — intervention group
Group type: EXPERIMENTAL
Intervention: More recently established communities with recent immigrants
Number of subjects: 906
Study 30653786 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese females
Number of subjects: 56
Study 30653786 — intervention group
Group type: COMPARATOR
Intervention: Normal-weight controls
Number of subjects: 56
Study 30653818 — intervention group
Group type: EXPERIMENTAL
Intervention: Bladder EpiCheck test
Number of subjects: 440
Study 30654137 — intervention group
Group type: EXPERIMENTAL
Intervention: Plerixafor (240 μg/kg s.c.) administered before conditioning chemotherapy (fludarabine and busulfan) for 1 to 4 days depending on the cohort.
Number of subjects: 12
Study 30654246 — intervention group
Group type: EXPERIMENTAL
Intervention: Alemtuzumab with enhanced infusion-associated reaction (IAR) prophylaxis
Number of subjects: 58
Study 30654246 — intervention group
Group type: EXPERIMENTAL
Intervention: Alemtuzumab with enhanced IAR prophylaxis
Number of subjects: 58
Study 30654810 — intervention group
Group type: EXPERIMENTAL
Intervention: Cadence thresholds of 100 steps/min for moderate intensity (3 METs)
Number of subjects: 76
Study 30654810 — intervention group
Group type: EXPERIMENTAL
Intervention: Cadence thresholds of 130 steps/min for vigorous intensity (6 METs)
Number of subjects: 76
Study 30654810 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal cadence thresholds using regression model
Number of subjects: 76
Study 30654810 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal cadence thresholds using ROC models
Number of subjects: 76
Study 30655164 — intervention group
Group type: EXPERIMENTAL
Intervention: TCR-modified T cells
Number of subjects: 0
Study 30655164 — intervention group
Group type: EXPERIMENTAL
Intervention: TCR gene-modified cells
Number of subjects: 0
Study 30655366 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 30655385 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with high-risk HLA genotypes (specific details not provided)
Number of subjects: 0
Study 30655690 — intervention group
Group type: EXPERIMENTAL
Intervention: active tDCS and active EIMS (a-tDCS/a-EIMS)
Number of subjects: 60
Study 30655690 — intervention group
Group type: COMPARATOR
Intervention: sham tDCS and sham EIMS (s-tDCS/s-EIMS)
Number of subjects: 60
Study 30655690 — intervention group
Group type: COMPARATOR
Intervention: active tDCS and sham EIMS (a-tDCS/s-EIMS)
Number of subjects: 60
Study 30655690 — intervention group
Group type: COMPARATOR
Intervention: sham tDCS and active EIMS (s-tDCS/a-EIMS)
Number of subjects: 60
Study 30656132 — intervention group
Group type: EXPERIMENTAL
Intervention: Physically active academic lessons
Number of subjects: 447
Study 30656154 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Movement Screen (FMS) scores
Number of subjects: 51
Study 30656241 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearable sensor device for detection of atrial fibrillation
Number of subjects: 2659
Study 30656241 — intervention group
Group type: COMPARATOR
Intervention: Email invitation
Number of subjects: 2659
Study 30656241 — intervention group
Group type: EXPERIMENTAL
Intervention: Five-step outreach process (three short personalized emails and two direct mailers)
Number of subjects: 2659
Study 30656241 — intervention group
Group type: EXPERIMENTAL
Intervention: Messaging highlighting access to new technology
Number of subjects: 2659
Study 30656283 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic rFIXFc with a ≥14-day dosing interval
Number of subjects: 22
Study 30656479 — intervention group
Group type: EXPERIMENTAL
Intervention: EIT-guided PEEP titration
Number of subjects: 24
Study 30656479 — intervention group
Group type: COMPARATOR
Intervention: Pressure-volume curve-guided PEEP titration
Number of subjects: 24
Study 30656602 — intervention group
Group type: EXPERIMENTAL
Intervention: Reappraisal
Number of subjects: 35
Study 30656602 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance
Number of subjects: 35
Study 30657083 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurses with LBP
Number of subjects: 120
Study 30657083 — intervention group
Group type: COMPARATOR
Intervention: Nurses without LBP
Number of subjects: 120
Study 30657223 — intervention group
Group type: EXPERIMENTAL
Intervention: Aflibercept (4 mg/kg) plus FOLFIRI administered every 2 weeks
Number of subjects: 62
Study 30657405 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal PVP timing (194 patients)
Number of subjects: 291
Study 30657405 — intervention group
Group type: EXPERIMENTAL
Intervention: Early PVP timing (52 patients)
Number of subjects: 291
Study 30657405 — intervention group
Group type: EXPERIMENTAL
Intervention: Late PVP timing (45 patients)
Number of subjects: 291
Study 30657405 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population (291 patients)
Number of subjects: 291
Study 30657405 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-aided quality-control system
Number of subjects: 291
Study 30657642 — intervention group
Group type: EXPERIMENTAL
Intervention: PrEP
Number of subjects: 93
Study 30657642 — intervention group
Group type: EXPERIMENTAL
Intervention: ART
Number of subjects: 93
Study 30657884 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal BMI group (<25.0 kg/m2)
Number of subjects: 1568
Study 30657884 — intervention group
Group type: EXPERIMENTAL
Intervention: Overweight BMI group (25.0-29.9 kg/m2)
Number of subjects: 1568
Study 30657884 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity BMI group (≥30.0 kg/m2)
Number of subjects: 1568
Study 30657884 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects in the same BMI group at CCTA1 and CCTA2 (1424 subjects, 90.8%)
Number of subjects: 1568
Study 30657884 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects with change in BMI group at CCTA2 (144 subjects, 9.2%)
Number of subjects: 1568
Study 30657884 — intervention group
Group type: EXPERIMENTAL
Intervention: Percent change of BMI
Number of subjects: 1568
Study 30657884 — intervention group
Group type: EXPERIMENTAL
Intervention: Male gender
Number of subjects: 1568
Study 30657884 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline plaque volume
Number of subjects: 1568
Study 30657884 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline overweight or obesity
Number of subjects: 1568
Study 30657914 — intervention group
Group type: EXPERIMENTAL
Intervention: Dairy intake (100 g/d increase)
Number of subjects: 6671
Study 30657914 — intervention group
Group type: EXPERIMENTAL
Intervention: Fruit and vegetable intake (100 g/d increase)
Number of subjects: 6671
Study 30657914 — intervention group
Group type: EXPERIMENTAL
Intervention: Fruit and vegetable intake
Number of subjects: 6671
Study 30657914 — intervention group
Group type: EXPERIMENTAL
Intervention: Sweet snacks intake
Number of subjects: 6671
Study 30657914 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish intake
Number of subjects: 6671
Study 30657914 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant-based fat and oil intake
Number of subjects: 6671
Study 30657926 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline for 12 weeks and six guideline-based smoking cessation counseling sessions
Number of subjects: 449
Study 30657926 — intervention group
Group type: EXPERIMENTAL
Intervention: Home ownership (yes/no)
Number of subjects: 449
Study 30657926 — intervention group
Group type: EXPERIMENTAL
Intervention: Study visits completed (range=0-6)
Number of subjects: 449
Study 30657926 — intervention group
Group type: EXPERIMENTAL
Intervention: Income (household member/$1000)
Number of subjects: 449
Study 30657926 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma cotinine (per 1 ng/mL)
Number of subjects: 449
Study 30657926 — intervention group
Group type: EXPERIMENTAL
Intervention: Neighborhood problems (range=10-30)
Number of subjects: 449
Study 30658128 — intervention group
Group type: EXPERIMENTAL
Intervention: 9-valent HPV vaccine
Number of subjects: 145
Study 30658648 — intervention group
Group type: EXPERIMENTAL
Intervention: Interprofessional clinical training
Number of subjects: 195
Study 30658648 — intervention group
Group type: COMPARATOR
Intervention: Conventional clinical training
Number of subjects: 195
Study 30658992 — intervention group
Group type: EXPERIMENTAL
Intervention: Pediatric ALL regimen administered by adult treatment teams
Number of subjects: 295
Study 30658992 — intervention group
Group type: COMPARATOR
Intervention: Historical control
Number of subjects: 295
Study 30659040 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose chest CT (LDCT) screening
Number of subjects: 2537
Study 30659076 — intervention group
Group type: EXPERIMENTAL
Intervention: Urban population
Number of subjects: 0
Study 30659076 — intervention group
Group type: EXPERIMENTAL
Intervention: Town population
Number of subjects: 0
Study 30659076 — intervention group
Group type: EXPERIMENTAL
Intervention: Periurban villages (PUVs)
Number of subjects: 0
Study 30659076 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal obesity
Number of subjects: 0
Study 30659892 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative radiotherapy (20-40 Gy)
Number of subjects: 15
Study 30659892 — intervention group
Group type: COMPARATOR
Intervention: Control (standard therapy)
Number of subjects: 15
Study 30660511 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab (240 mg every 2 weeks) plus ipilimumab (1 mg/kg every 6 weeks up to four times)
Number of subjects: 34
Study 30660511 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab plus ipilimumab
Number of subjects: 34
Study 30660617 — intervention group
Group type: EXPERIMENTAL
Intervention: Grazoprevir 100 mg plus Elbasvir 50 mg (8 weeks treatment)
Number of subjects: 80
Study 30661037 — intervention group
Group type: EXPERIMENTAL
Intervention: High educational attainment (senior high school, college or postgraduate degree)
Number of subjects: 3369